CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

		(Rupees in Thousand			
Sr. No.	Particulars		Quarter Ended	Author audion to the property	Year Ended
		30th June 2019	31st March 2019	30th June 2018	31st March 2019
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations				100
II	Other Income	2,831	4,266	1,240	8,225
Ш	Total Revenue (I + II)	2,831	4,266	1,240	8,225
IV .	Expenses				
	(1) Cost Materials consumed			-	
	(2) Purchase of Stock-in-Trade	-	-		
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade			-	
	(4) Employee Benefits Expenses	405	526	563	2,218
	(5) Depreciation and Amortisation Expenses	(2)	-		47
	(6) Administrative and Other Expenses	923	854	601	3,414
1	i) Annual Listing Fees		-	310	
	ii) Travellling Expenses	-		268	-
	(7) Finance Costs	*	-	-	-
	Total Expenses	1,328	1,380	1,742	5,679
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	1,503	2,886	(502)	2,546
VI	Exceptional Items	-	(4)	1 H	
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	1,503	2,886	(502)	2,546
VIII	Extra Ordinary Items	_	-	些	14
IX	Profit/(Loss) before Tax (VII-VIII)	1,503	2,886	(502)	2,546
Х	Tax Expenses				
	(1) Current Tax	÷	460	2	460
	(2) Tax Adjustment Previous Year	-/-			23
	(3) Deffered Tax	-		9	12
XI	Profit/(Loss) for the period from continuing operations (IX - X)	1,503	2,426	(502)	2,063
XII	Profit/(Loss) from discontinuing operations	-			-
XIII	Tax Expenses of discontinuing operations		-	-	
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	12 0#0		-	-
XV	Profit/(Loss) for the period (XI - XIV)	1,503	2,426	(502)	2,063
XVI	Other Comprehensive Income A (i) Itmes that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to profit or loss B (i) Itmes that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be reclassified to	2,000		(302)	
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	1,503	2,426	(502)	2,063
XVIII	Earnings per Share: (1) Basic (2) Diluted	1.00	1.62	(0.33)	1.38

Notes:

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter Ended 30.06.2019 have been reviewed by the Audit Committee in their Meeting held on 18.07.2019 and approved by the Board of Directors of its Meeting held on 18.07.2019. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited

Ashok Somani Director

Place: Mumbai

Date: 18th July, 2019



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L999999MH1942PLC003556 • PAN No.: AAACC2056K Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATON OF STANDLONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2019

(Rs. In Thousand)

	STANDLONE		
PARTICULARS	UNAUDITED QUARTER ENDED 30.06.2019	AUDITED YEAR ENDED 31.03.2019	
Reconciliation of Profit After Tax as reported earlier:			
Net Profit / (Loss) for the Period (as per AS)	1,503	2,063	
Benefit / (Charge):		2,000	
Impact of Deferred Income (Government Grant) Amortized to Income	-		
Impact of Fair Valuation of Financial Instruments	_		
Impact of Actuarial Gain / Loss Taken OCI	_	_	
Impact of Adjustment of Deferred Tax	•		
Net Profit / (Loss) for the Period (as per AS)	1,503	2,063	

or Chemo Pharma Laboratories Ltd.

Ashok Somani Director

Mumbai, 18th July, 2019